A Long-Term Study of Efficacy of Patients with Macular Edema Secondary to BRVO Treated with Ranibizumab Combined with Compound Salvia

Xingwei  Wu; Yalan  Feng

doi:10.4236/cm.2015.63018

Yalan Feng, Xingwei Wu^*

Abstract: Purpose: To study the long-term efficacy of intravitreal ranibizumab injection combined with in-travenous compound salvia injection drip in the treatment of patients with macular edema sec-ondary to branch retinal vein occlusion(BRVO). Methods: Sixty-five patients of branch retinal vein occlusion with macular edema were analyzed retrospectively. Thirty-seven patients in the treat-ment group were treated with ranibizumab injection combined with intravenous compound salvia injection drip, twenty-eight patients in the control group were treated with ranibizumab injection only. All patients were recorded and analyzed changes of clinical efficacy after 3 months, 6 months after a course of treatment of 6 months. Results: During 3 months after 6 months’ treatment, there were 5 patients having recurrence in the treatment group, while there were 9 in control group, the rate of recurrence between the two groups had significant difference (P < 0.05); during 3 - 6 months after a course of treatment, there were 2 patients having recurrence in the treatment group, while there were 4 in control group, the rate of recurrence between the two groups had significant difference (P < 0.05); however, the treatment group’s BCVA was better than control group, and the difference between the two groups had significance (P < 0.05). Conclusion: Ranibizumab injection combined with intravenous compound salvia injection drip could effectively reduce the impossibility of recurrence, improve the visual activity and bring better therapeutic efficacy in patients with macular edema secondary to branch retinal vein occlusion. The treatment showed great potential in the clinical use.

Keywords: Branch Retinal Vein Occlusion, Macular Edema, Long-Term Follow-Up, Ranibizumab, Compound Salvia

Cite this paper: Feng, Y. and Wu, X. (2015) A Long-Term Study of Efficacy of Patients with Macular Edema Secondary to BRVO Treated with Ranibizumab Combined with Compound Salvia. Chinese Medicine, 6, 169-174. doi: 10.4236/cm.2015.63018.

References

[1] Campochiaro, P.A. (2012) Anti-Vascular Endothelial Growth Factor Treatment for Retinal Vein Occlusions. Ophthalmologica, 227, 30-35.
http://dx.doi.org/10.1159/000337157

[2] Spaide, R.F., Chang, L.K., Klancnik, J.M., Yannuzzi, L.A., Sorenson, J., Slakter, J.S., et al. (2009) Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity Secondary to Central Retinal Vein Occlusion. American Journal of Ophthalmology, 147, 298-306. http://dx.doi.org/10.1016/j.ajo.2008.08.016

[3] Pieramici, D.J., Rabena, M., Castellarin, A.A., Nasir, M., See, R., Norton, T., et al. (2008) Ranibizumab for the Treatment of Macular Edema Associated with Perfused Central Retinal Vein Occlusions. Ophthalmology, 115, 47-54.
http://dx.doi.org/10.1016/j.ophtha.2008.06.021

[4] Antonetti, D.A., Barber, A.J., Khin, S., Lieth, E., Tarbell, J.M. and Garnder, T.W. (1998) Vascular Permeability in Experiment Diabetes Is Associated with Reduced Endothelial Occludin Content: Vascular Endothelial Growth Factor Decreases Occludin in Retinal Endothelial Cells. Penn State Retina Research Group. Diabetes, 47, 1953-1959.
http://dx.doi.org/10.2337/diabetes.47.12.1953

[5] Rehak, J. and Rehak, M. (2008) Branch Retinal Vein Occlusion: Pathogenesis, Visual Prognosis, and Treatment Modalities. Current Eye Research, 33, 111-131.
http://dx.doi.org/10.1080/02713680701851902

[6] Lu, B.W. and Wu, X.W. (2013) Clinical Study on Traditional Chinese Medicine in the Treatment of Patients with Macular Edema Secondary to Retinal Vein Occlusion. China Journal of Chinese Ophthalmology, 23, 328-333.

[7] Hahn, P. and Fekrat, S. (2012) Best Practices for Treatment of Retinal Vein Occlusion. Current Opinion in Ophthalmology, 23, 175-181.
http://dx.doi.org/10.1097/ICU.0b013e3283524148

[8] Feng, Y.L. and Wu, XW. (2015) Ranibizumab Combined with Compound Salvia in Treating Macular Edema Secondary to Branch Retinal Vein Occlusion. Chinese Journal of Ocular Fundus Diseases, 25, 107-110.

[9] Chatziralli, I.P., Jaulim, A., Peponis, V.G., Mitropoulos, P.G. and Moschos, M.M. (2014) Branch Retunal Vein Occlusion: Treatment Modalities: An Update of the Literature. Seminars in Ophthalmology, 29, 85-107.
http://dx.doi.org/10.3109/08820538.2013.833271

[10] Noma, H., Funatsu, H., Yamasaki, M., Tsukamoto, H., Mimura, T., Sone, T., et al. (2008) Aqueous Humour Levels of Cytokines Are Correlated to Vitreous Levels and Severity of Macular Oedema in Branch Retinal Vein Occlusion. Eye, 22, 42-48.
http://dx.doi.org/10.1038/sj.eye.6702498

[11] Blick, S.K., Keating, G.M. and Wagstaff, A.J. (2007) Ranibizumab. Drugs, 67, 1199-1206.
http://dx.doi.org/10.2165/00003495-200767080-00007

[12] Ferrara, N., Damico, L., Shams, N., Lowman, H. and Kim, R. (2006) Development of Ranibizumab, an Anti-Vascular Endothelial Growth Factor Antigen Binding Fragment, as Therapy for Neovascular Age-Related Macular Degeneration. Retina, 26, 859-870.
http://dx.doi.org/10.1097/01.iae.0000242842.14624.e7

[13] Ferrara, N. (2010) Vascular Endothelial Growth Factor and Age-Related Macular Degeneration: From Basic Science to Therapy. Nature Medicine, 16, 1107-1111.
http://dx.doi.org/10.1038/nm1010-1107

[14] Brown, D.M., Campochiaro, P.A., Bhisitkul, R.B., Ho, A.C., Gray, S., Saroj, N., et al. (2011) Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study. Ophthalmology, 118, 1594-1602.
http://dx.doi.org/10.1016/j.ophtha.2011.02.022

[15] Tan, M.H., Mcallister, I.L., Gillies, M.E., Verma, N., Banerjee, G., Smithies, L.A., Wong, W.-L. and Wong, T.Y. (2014) Randomized Controlled Trial of Intravitreal Ranibizumab versus Standard Grid Laser for Macular Edema Following Branch Retinal Vein Occlusion. American Journal of Ophthalmology, 157, 237-247.
http://dx.doi.org/10.1016/j.ajo.2013.08.013

[16] Gallego-Pinazo, R., Dolz-Marco, R., Pardo-López, D., Martínez-Castillo, S., Lleó-Pérez, A., Arévalo, J.F. and Díaz-Llopis, M. (2013) Ranibizumab for Serous Macular Detachment in Branch Retinal Vein Occlusions. Graefe’s Archive for Clinical and Experimental Ophthalmology, 251, 9-14. http://dx.doi.org/10.1007/s00417-012-2023-7

[17] Lu, B.W. and Wu, X.W. (2013) Recent Advances in Therapy for Macular Edema Secondary to Retinal Vein Occlusion. Chinese Journal of Ocular Fundus Diseases, 29, 640-644.

[18] Wang, Z.C. (2006) The Discussion of the Efficacy and Adversereaction of Salvia Injection. Chinese Medical Journal, 4, 545-546.

[19] Pan, L.X. (2003) Low Molecular Dextran Combine with Compound Salvia in the Treatment of BRVO. Journal of Practical Medical Techniques, 10, 1026-1027.

[20] Zhang, X.Y., Li, Y.B., Zhou, L.W., Wang, X.B. and Luo, X.D. (2014) Ranibizumab Combined with Grid Laser in the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion. International Journal of Ophthalmology, 14, 47-49.

[21] Zhang, H., Liu, Y.-Y., Jiang, Q., Li, K.-R., Zhao, Y.-X., Cao, C. and Yao, J. (2014) Salvianolic Acid A Protects RPE Cells against Oxidative Stress through Activation of Nrf2/HO-1 Signaling. Free Radical Biology and Medicine, 69, 219-228.
http://dx.doi.org/10.1016/j.freeradbiomed.2014.01.025

[22] Xu, G.X., Peng, Y.H. and Yue, Z.Z. (2006) Observation on Therapeutic Effects of Diabetes with Peripheral Nervus Disease Treated with compound salvia and mecobalamin. Chinese Journal of Rural Medicine and Pharmacy, 13, 18-19.